“Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD”. Ariel A. Calderon, Colin Dimond, David F. Choy, Rajita Pappu, Michele A. Grimbaldeston, Divya Mohan and Kian Fan Chung. Eur Respir Rev 2023; 32: 220144

The authors of this review, published in the March 2023 issue, requested to clarify the following sentence:

“In COPD, TSLP production in bronchial epithelial cells may be mediated by Th17, suggesting that anticholinergics may exert an anti-inflammatory effect in COPD via TSLP [111] and that the role of TSLP in COPD may be more limited to airway smooth muscles.”

This has been corrected to read:

“In COPD, TSLP production in bronchial epithelial cells and involvement in releasing acetylcholine may be mediated by Th17, suggesting that anticholinergics may exert an anti-inflammatory effect in COPD via TSLP [111] and that the role of TSLP in COPD may be more limited to airway smooth muscles.”

In addition, in table 1 the Key results summary for the entry NCT03347279 [117] NAVIGATOR study Tezepelumab (anti-TSLP) has been corrected based on information presented in reference 117 in the review. The published table summary read:

“66% exacerbation rate reduction (p<0.001), FEV₁ improvement of 0.13 L (p<0.001) for 210 mg dose in comparison with placebo”

This has been corrected to:

“56% exacerbation rate reduction (p<0.001), FEV₁ improvement of 0.13 L (p<0.001) for 210 mg dose in comparison with placebo”

Finally, a minor typographical error has been corrected in the first sentence of the section Insights from clinical trials. The sentence now reads:

“Within the last 10 years, trials with biological drugs targeting the IL-33/ST2 and anti-TSLP pathways in asthma and COPD have been and continue to be undertaken (table 1).”

The article has been corrected and republished online.